

Standing Orders for Administering Pneumococcal (PPSV23 and PCV13) Vaccine in Adults

Purpose: To reduce morbidity and mortality from pneumococcal disease by vaccinating all adults who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

Policy: Under these standing orders, eligible nurses and other healthcare professionals working within their scope of practice may vaccinate adult patients who meet the criteria below.

Procedure

1. Identify adults in need of vaccination with pneumococcal conjugate vaccine (PCV13) based on the following criteria:
 - age 65 years or older with no or unknown history of prior receipt of PCV13
 - age 18-64 years with no or unknown history of prior receipt of PCV13 and any of the following underlying conditions:
 - candidate for or recipient of cochlear implant; cerebrospinal fluid leak
 - functional or anatomic asplenia (e.g., sickle cell disease, splenectomy)
 - Immunocompromising condition (e.g., HIV infection, congenital immunodeficiency, hematologic and solid tumors)
 - immunosuppressive therapy (e.g., alkylating agents, antimetabolites, long-term systemic corticosteroids, radiation therapy, biologics).
 - organ or bone marrow transplantation; chronic renal failure or nephrotic syndrome
 - **Note:** PCV13 vaccine in persons aged 18-49 years is **considered off-label**, despite representing the current standard of care, and patients should be counseled by their provider about the use of this vaccine for their condition.
2. Identify adults in need of vaccination with pneumococcal polysaccharide vaccine (PPSV23) based on the following criteria:
 - age 65 years or older with no or unknown history of prior receipt of PPSV23
 - age 18 through 64 years with no or unknown history of prior receipt of PPSV23 and any of the following underlying conditions:
 - chronic cardiovascular disease (e.g., congestive heart failure, cardiomyopathies)
 - chronic pulmonary disease (e.g., chronic obstructive pulmonary disease, emphysema, asthma)
 - diabetes mellitus, alcoholism or chronic liver disease (cirrhosis), cigarette smoker, or long-term care facility resident
 - any of the conditions specified in categories above
3. Identify adults in need of a single additional dose of PPSV23 **if 5 or more years have elapsed** since their first dose of PPSV23 and the patient meets one of the following criteria:
 - age 65 years or older and received prior PPSV vaccination before age 65 years
 - age 18 through 64 years and at highest risk for serious pneumococcal infection or likely to have a rapid decline in pneumococcal antibody levels (i.e., bullets above)
4. Screen all patients for contraindications and precautions to PCV13 or PPSV23 vaccine:

Contraindications:

- a history of a serious reaction (e.g., anaphylaxis) after a previous dose of

PCV13/ PPSV23 vaccine or to a PCV13/PPSV23 vaccine component. For a list of vaccine components, please see the [manufacturer's package insert](#) or go to <http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf>

Precautions:

- moderate or severe acute illness with or without fever
 - For questions or concerns, consider consulting the DHA Immunization Healthcare Branch at 877-438-8222, Option 1.
5. Provide all patients (or their parent/legal representative) with a copy of the most current federal [Vaccine Information Statement \(VIS\)](#). You must document, in the patient's medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.
 6. Administer vaccine as follows:
 - for adults identified in #1 above, administer 0.5 mL PCV13 intramuscularly (22–25 gauge, 1–1½" needle) in the deltoid muscle.
 - for adults identified in #2 and #3 above, administer 0.5 mL PPSV23 vaccine either intramuscularly (22–25 gauge, 1–1½" needle) in the deltoid muscle or subcutaneously (23–25 gauge, 5/8" needle) in the posterolateral fat of the upper arm.
 - for adults in need of both PCV13 and PPSV23, administer PCV13 first, followed by PPSV23 in 12 months. (**Note:** for adults with immunocompromising conditions or functional or anatomic asplenia, give PPSV23 eight (8) weeks following PCV13.) If previously vaccinated with PPSV23, give PCV13 at least 12 months following PPSV23. **Do not give PCV13 and PPSV23 at the same visit.**
 7. Documentation
 - Document all immunizations administered in the electronic health record. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.
 8. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.
 9. Adverse Events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (1-800-822-7967) or online at <https://vaers.hhs.gov>.
 10. This policy and procedure shall remain in effect for all patients of the _____ until rescinded and/or upon a change in the Medical Director, whichever is earlier.


Medical Director's Signature

Date

Pneumococcal Vaccine Timing


Age 65 Years or Older – Everyone

- If PCV13 was given before age 65 years, no additional PCV13 is needed.



Age 19-64 Years – Underlying Conditions

- Prior doses count towards doses recommended below and do not need to be repeated.
- If PPSV23 given previously – wait one year before giving PCV13
 - when dose indicated, wait at least five years before giving a second dose of PPSV23.



• **DO NOT administer PCV13 and PPSV23 at the same visit.**